Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00518362
Status:
COMPLETED
Last Update Posted:
2010-05-27
First Post:
2007-08-16
Brief Title:
To Compare the Efficacy and Safety of Tripterygium TW Versus Valsartan in the Diabetic Nephropathy DN
Sponsor:
Nanjing University School of Medicine
Organization:
Nanjing University School of Medicine
Study Overview
Official Title:
To Compare the Efficacy and Safety of TW vs Valsartan in the DN
Status:
COMPLETED
Status Verified Date:
2009-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the efficacy and safety of Tripterygium TW versus Valsartan ARB in the Diabetic Nephropathy DN
Detailed Description:
Diabetic nephropathy with heavy proteinuria have high risks of progressing to end stage renal disease Though recent studies have shown that ACEI or ARB could reduce proteinuria of DN and slowed the progression to ESRD But ARBs can only reduce proteinuria about 30 so some patients still have heavy proteinuriaand then loss their renal function rapidly So to reduce the proteinuria of DN is a very important therapy target
Tripterygium TW is a Chinese traditional patent drug it can reduce proteinuria of chronic glomerular nephritis So we designed this randomized prospective clinical trial to assess the efficacy and safety of TW versus ARB in the treatment of heavy proteinuria of DN
Tripterygium TW is a Chinese traditional patent drug it can reduce proteinuria of chronic glomerular nephritis So we designed this randomized prospective clinical trial to assess the efficacy and safety of TW versus ARB in the treatment of heavy proteinuria of DN
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None